Interest of a dermo-cosmetic product in the prevention of eyelids dermatitis relapses

After 168 days, a mean of 0.67 relapses were observed vs. 5.09 in the control group (p<0.001), corresponding to a decrease of 85% in the product group. Moreover, 76% of the subjects in the product group presented no relapse, whereas all subject presented at least one relapse in the control group. The mean time of the relapse delay was 29 days vs. 32 days in the control group. A significant decrease of DLQI scores between the two groups indicated that the product had a positive impact on the quality of life in atopic patients. Furthermore, 91% to 100% of the subjects agreed that the product left the skin comfortable and repaired, soothed irritation, itching, and dryness, and prevented irritation. The product was very well-tolerated by all subjects.

By its preventing effect, this dermo-cosmetic product offers a real interest in management of atopic dermatitis eyelids and relieves the chronic disease burden of atopic subjects.

Sandrine Bergera-Virassamynaïk¹, Marlène Chavagnac-Bonneville^1,2, Christelle Graizeau^1,2 and Michèle Sayag¹

¹NAOS Group, Research and Development Department, Aix-en-Provence, France

²NAOS Institute of Life Science, Aix-en-Provence, France

Bergera-Virassamynaïk S. and Sayag M.

NAOS, Research and Development Department, Lyon, France